Cocrystal Pharma (NASDAQ:COCP) Director Purchases $47,500.00 in Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost purchased 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $47,500.00. Following the transaction, the director directly owned 1,888,551 shares of the company’s stock, valued at $1,794,123.45. The trade was a 2.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 31st, Phillip Md Et Al Frost acquired 50,000 shares of Cocrystal Pharma stock. The shares were bought at an average cost of $0.95 per share, with a total value of $47,500.00.
• On Tuesday, December 30th, Phillip Md Et Al Frost acquired 20,000 shares of Cocrystal Pharma stock. The shares were purchased at an average price of $0.97 per share, with a total value of $19,400.00.
• On Friday, December 26th, Phillip Md Et Al Frost bought 40,000 shares of Cocrystal Pharma stock. The stock was purchased at an average cost of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, December 24th, Phillip Md Et Al Frost bought 25,000 shares of Cocrystal Pharma stock. The stock was purchased at an average price of $0.97 per share, for a total transaction of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The shares were purchased at an average cost of $0.99 per share, with a total value of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The shares were purchased at an average price of $0.94 per share, with a total value of $18,800.00.

Cocrystal Pharma Trading Down 1.9%

Shares of Cocrystal Pharma stock traded down $0.02 during trading hours on Monday, reaching $0.95. The stock had a trading volume of 46,527 shares, compared to its average volume of 90,473. The firm has a market capitalization of $13.11 million, a price-to-earnings ratio of -1.01 and a beta of 1.20. Cocrystal Pharma, Inc. has a 1 year low of $0.86 and a 1 year high of $2.67. The firm has a 50 day simple moving average of $1.03 and a two-hundred day simple moving average of $1.21.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. Sell-side analysts forecast that Cocrystal Pharma, Inc. will post -1.85 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cocrystal Pharma currently has an average rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.